Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRD-002
- Development stage
- Preclinical
- Lead developer
- Sardocor
- Modality
- Small Molecules
- Administration
- Intracoronary Infusion
01
Overview
SRD-002 is a small molecule activator of the sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a) being developed by Sardocor for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). SERCA2a is a calcium pump that plays a vital role in cardiomyocyte relaxation by sequestering calcium into the sarcoplasmic reticulum during diastole. Impaired SERCA2a activity is a hallmark of heart failure, leading to poor calcium handling and diastolic dysfunction. By enhancing SERCA2a function, SRD-002 aims to improve cardiac relaxation and overall heart function in patients with HFpEF. The program is currently in the preclinical stage of development.
02
Targets
ATP2A2 (Sarco/endoplasmic reticulum calcium ATPase isoform 2a)
Beyond the preview
Go deeper on SRD-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRD-002.